Overview

Vilazodone for Separation Anxiety Disorder

Status:
Completed

Trial end date:
2017-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.

Phase:

Phase 4

Details

Lead Sponsor:

New York State Psychiatric Institute

Collaborator:

Forest Laboratories

Treatments:

Vilazodone Hydrochloride